Maravai LifeSciences Holdings Revenue | MRVI

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Maravai LifeSciences Holdings

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
186 M	259 M	289 M	883 M	799 M	284 M	143 M	124 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
883 M	124 M	371 M

Quarterly Revenue Maravai LifeSciences Holdings

2026-Q2	2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
51.4 M	65.8 M	41.6 M	47.4 M	46.8 M	69 M	69.4 M	64.2 M	66.9 M	68.9 M	79 M	-	191 M	243 M	244 M	-	205 M	218 M	148 M	-	87.9 M	46.9 M	51 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
244 M	41.6 M	105 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Wave Life Sciences Ltd. WVE	42.7 M	$ 3.18	-0.16 %	$ 536 M	Singapore
Xenetic Biosciences XBIO	2.98 M	$ 1.83	6.4 %	$ 3.11 M	USA
XBiotech XBIT	4.01 M	$ 1.85	-4.15 %	$ 56.4 M	USA
Xenon Pharmaceuticals XENE	7.5 M	$ 35.44	0.28 %	$ 2.81 B	Canada
Xeris Pharmaceuticals XERS	292 M	$ 10.34	1.37 %	$ 1.66 B	USA
X4 Pharmaceuticals XFOR	6.5 M	$ 3.25	0.15 %	$ 137 M	USA
XTL Biopharmaceuticals Ltd. XTLB	451 K	$ 2.02	2.54 %	$ 1.36 B	Israel
22nd Century Group XXII	17.6 M	$ 0.09	-53.06 %	$ 16.6 K	USA
Silence Therapeutics plc SLN	5.3 M	$ 19.72	0.25 %	$ 2.79 B	Britain
Zai Lab Limited ZLAB	460 M	$ 24.15	0.5 %	$ 26.5 B	China
Zentalis Pharmaceuticals ZNTL	67.4 M	$ 2.13	-3.85 %	$ 153 M	USA
Revolution Medicines RVMD	11.6 M	$ 184.88	-1.13 %	$ 35.2 B	USA
Zoetis ZTS	9.47 B	$ 80.41	-0.77 %	$ 35.7 B	USA
Zymeworks ZYME	26.7 M	$ 27.87	-1.24 %	$ 1.44 B	Canada
Akari Therapeutics, Plc AKTX	368 K	$ 8.35	1.52 %	$ 562 B	Britain
Alector ALEC	21 M	$ 1.89	3.28 %	$ 195 M	USA
Aligos Therapeutics ALGS	2.19 M	$ 4.59	-3.97 %	$ 45.4 M	USA
Alkermes plc ALKS	1.48 B	$ 44.29	1.51 %	$ 7.29 B	Irlanda
Allogene Therapeutics ALLO	22 K	$ 1.23	-1.5 %	$ 271 M	USA
Cleveland BioLabs, Inc. CBLI	263 K	-	-7.31 %	$ 49 M	USA
Amgen AMGN	36.8 B	$ 440.91	0.37 %	$ 237 B	USA
Amarin Corporation plc AMRN	214 M	$ 12.08	2.46 %	$ 5.01 B	Irlanda
Amneal Pharmaceuticals AMRX	3.02 B	$ 21.09	3.46 %	$ 6.61 B	USA
AnaptysBio ANAB	53 M	$ 48.68	-0.1 %	$ 1.41 B	USA
Aclaris Therapeutics ACRS	7.83 M	$ 3.82	1.73 %	$ 468 M	USA
AC Immune SA ACIU	3.57 M	$ 2.33	-3.93 %	$ 235 M	Schweiz
Five Prime Therapeutics, Inc. FPRX	13.2 M	-	-	$ 1.77 B	USA
Adagene ADAG	7.67 M	$ 2.46	1.87 %	$ 145 M	China
ADMA Biologics ADMA	510 M	$ 10.98	2.76 %	$ 2.62 B	USA
Adaptive Biotechnologies Corporation ADPT	277 M	$ 26.29	3.06 %	$ 3.99 B	USA
Agenus AGEN	114 M	$ 6.21	-1.9 %	$ 185 M	USA
Agios Pharmaceuticals AGIO	54 M	$ 37.19	0.51 %	$ 2.16 B	USA
Arbutus Biopharma Corporation ABUS	14.1 M	$ 4.22	0.48 %	$ 809 M	Canada
ADC Therapeutics SA ADCT	81.4 M	$ 1.51	4.15 %	$ 192 M	Schweiz
AbbVie ABBV	16.6 B	$ 286.17	0.2 %	$ 506 B	USA
ACADIA Pharmaceuticals ACAD	1.07 B	$ 19.64	-0.46 %	$ 3.31 B	USA
Biofrontera AG BFRA	30.3 M	-	-8.24 %	$ 105 M	Germany
Aquestive Therapeutics AQST	44.5 M	$ 4.01	0.13 %	$ 429 M	USA
Armata Pharmaceuticals ARMP	823 K	$ 3.47	-4.55 %	$ 126 M	USA
Catabasis Pharmaceuticals, Inc. CATB	500 K	-	-6.97 %	$ 657 M	USA
Atara Biotherapeutics ATRA	121 M	$ 8.25	-3.96 %	$ 103 M	USA
China Biologic Products Holdings, Inc. CBPO	524 M	-	1.68 %	$ 4.65 B	China
Autolus Therapeutics plc AUTL	75.4 M	$ 1.53	-0.65 %	$ 407 M	Britain
Bicycle Therapeutics plc BCYC	72.6 M	$ 3.64	2.39 %	$ 252 M	Britain
BeyondSpring BYSI	1.35 M	$ 0.45	4.38 %	$ 18.5 M	USA
Flexion Therapeutics, Inc. FLXN	85.6 M	-	-	$ 459 M	USA
ANI Pharmaceuticals ANIP	883 M	$ 72.82	0.29 %	$ 1.46 B	USA
Ardelyx ARDX	407 M	$ 3.04	-1.46 %	$ 733 M	USA